Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide and Calorie Restrict Diet in Overweight/Obese PCOS Patients
NCT04876027Phase 4Completed
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- May 2021
- Primary completion
- Apr 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised trial of dulaglutide in polycystic ovary syndrome (PCOS) (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: Change in Visceral Adipose Tissue at 12 weeks. Started May 2021; status: completed.
02
Drugs
dulaglutide
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT04876027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04876027.